Drug Profile
AF 106
Alternative Names: AF-106Latest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Afimmune
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 07 Sep 2022 Preclinical development is ongoing in Ireland (Afimmune pipeline, September 2022)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in Ireland
- 27 Sep 2016 Preclinical trials in Inflammation in Ireland (unspecified route)